ACRS - Aclaris Therapeutics Stock Trading

Aclaris Therapeutics Inc.(NASDAQ: ACRS) stock trading, description, contact, officers and directors.

About Aclaris Therapeutics Inc.

Aclaris Therapeutics, Inc. is a clinical stage specialty pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in dermatology

Stock Information

Aclaris Therapeutics Inc. Company Name:

ACRS Stock Symbol:

NASDAQ Market:

Aclaris Therapeutics Inc. Website:

ACRS - Aclaris Therapeutics Stock Trading

ACRS ACRS Quote ACRS Short ACRS News ACRS Articles ACRS Message Board

Get ACRS Alerts

News, Short Squeeze, Breakout and More Instantly...

ACRS - Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference

WAYNE, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at th...
ACRS - Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

First Subject Dosed in Phase 2a Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis Initiated Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, for the Treatment of Cr...
ACRS - Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical "Soft" JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis

WAYNE, Pa., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the first patient has been dosed in Aclaris’ Phase 2a...